Search company, investor...
Neuro Kinetics company logo

Neuro Kinetics

neuro-kinetics.com

Founded Year

1984

Stage

Acquired | Acquired

Total Raised

$5.54M

About Neuro Kinetics

Neuro Kinetics develops clinical eye-tracking and non-invasive neurofunctional diagnostic testing, delivering edge neurofunctional assessments.

Headquarters Location

128 Gamma Drive

Pittsburgh, Pennsylvania, 15238,

United States

412-963-6649

Missing: Neuro Kinetics's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Neuro Kinetics's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Neuro Kinetics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Neuro Kinetics is included in 4 Expert Collections, including Medical Devices.

M

Medical Devices

11,693 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

H

Health Monitoring & Diagnostics

2,594 items

Companies developing or offering products that aid in the assessment, screening, diagnosis, or monitoring of a person's state of health/wellness. Excludes companies focused solely on fitness/sports performance

D

Digital Health

13,069 items

Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)

H

Health IT

7,901 items

Neuro Kinetics Patents

Neuro Kinetics has filed 30 patents.

The 3 most popular patent topics include:

  • Neurotrauma
  • Psychiatric diagnosis
  • Vision
patents chart

Application Date

Grant Date

Title

Related Topics

Status

2/14/2018

8/23/2022

Neurotrauma, Vision, Ophthalmology, Psychiatric diagnosis, Neurological disorders

Grant

Application Date

2/14/2018

Grant Date

8/23/2022

Title

Related Topics

Neurotrauma, Vision, Ophthalmology, Psychiatric diagnosis, Neurological disorders

Status

Grant

Latest Neuro Kinetics News

Neurolign Acquires of Eye Diagnostic Technology Company Neuro Kinetics

Oct 10, 2019

Terms of the deal were not disclosed. Neurolign is a privately held diagnostic and pharmaceutical company focused on bringing superior diagnostic solutions and novel therapeutics for the diagnosis and treatment of neurological conditions to physicians and their patients. Neurolign’s founder is Eugene Melnyk, the creator of multiple healthcare companies, including Biovail Corporation (acquired by Bausch Health), and the current owner of the Ottawa Senators Hockey Club. Through this transaction, Neurolign will acquire the assets and operations of Neuro Kinetics, including customer relationships, all products, technologies, related intellectual property, fixed assets, and will assume certain liabilities. “The acquisition of Neuro Kinetics accelerates Neurolign’s mission to research, develop and provide access to world-class diagnostics and targeted pharmaceutical therapeutics to improve the lives of patients suffering from neurological disorders, initially beginning with concussion,” Eugene Melnyk, Neurolign Chairman and Chief Executive Officer, said in a company news release. “After watching concussed athletes in sport, and its impact on these athletes and their families, there is a need to advance clinicians’ abilities to diagnose and determine when athletes can safely return to playing sports. We will address this through transforming not just diagnosis and treatment of concussion, but also for a wide array of neurological disorders affecting the global community.”  “Traumatic Brain Injury, TBI, is a global public health epidemic and an increasing concern in Military Health,” David Okonkwo, MD, PhD, Professor of Neurosurgery at the University of Pittsburgh and Director, Neurotrauma Clinical Trials Center, said in a the news release. “There is an urgent need for new innovative technologies that bring objective diagnostic data for TBI. This investment in Neuro Kinetics can accelerate the development and commercialization of this novel technology and take the lead in diagnostics across multiple dimensions of brain health.” Neuro Kinetics is a leader in providing eye-tracking platforms delivering the most precise and data-rich eye-tracking diagnostic solution in the global market to date. With over 90 variables and 14 FDA cleared tests, Neuro Kinetics solutions includes its critical assets, I-PAS and I-Portal. These foundational platforms help clinicians identify more than 200 diseases and medical conditions early, accurately, and cost-effectively. I-Portal’s non-invasive Science to See is enabling Neuro Kinetics to expand its presence in the vestibular market into new areas and applications in traumatic brain injury, concussion, ophthalmology, and neurology. “We look forward to the next phase of the company’s growth and development and are very excited to be merging with Neurolign,” Howison Schroeder, President and Chief Executive Officer of Neuro Kinetics. Schroeder said in the news release. “The opportunities created by this transaction provides us with the support we need to further advance our planned developments for the assessment of additional neurological diseases.” Related Content

Neuro Kinetics Frequently Asked Questions (FAQ)

  • When was Neuro Kinetics founded?

    Neuro Kinetics was founded in 1984.

  • Where is Neuro Kinetics's headquarters?

    Neuro Kinetics's headquarters is located at 128 Gamma Drive, Pittsburgh.

  • What is Neuro Kinetics's latest funding round?

    Neuro Kinetics's latest funding round is Acquired.

  • How much did Neuro Kinetics raise?

    Neuro Kinetics raised a total of $5.54M.

  • Who are the investors of Neuro Kinetics?

    Investors of Neuro Kinetics include Neurolign Technologies and Pittsburgh Life Sciences Greenhouse.

  • Who are Neuro Kinetics's competitors?

    Competitors of Neuro Kinetics include NeuroSky, Avantis Medical Systems, NeoGraft Technologies, Sonitus Medical, IntraOp Medical and 12 more.

Compare Neuro Kinetics to Competitors

NeuroSky Logo
NeuroSky

NeuroSky is at the forefront of body and mind monitoring and analysis. Its technologies are at the core of innovative, wearable health and wellness consumer products. NeuroSky makes it possible for millions of consumers to capture and quantify critical health and wellness data so that they can effectively manage their mind and body health. NeuroSky delivers uniquely adaptable chips and algorithms that offer ECG multi-function cardio monitoring, and quantitive and interpretive algorithms in a powerful integrated, adaptable and extensible solution.

W
Wioptix

Wioptix is a company that received a SBIR Phase IB grant for a project entitled: Development of Miniature Endoscopic Imaging Probes for In Vivo Noninvasive Optical Imaging for Early Diagnosis of Lung Cancer. Their Phase I project an Optical coherence tomography (OCT) imaging MEMS-based probe of 2.8 mm diameter will be designed and manufactured. The plan is to apply MEMS design and wire bonding free packaging techniques for miniaturization of the probe. In this MEMS design the mirror will have high fill factor and bonding pads on the opposite chip side of the reflective mirror surface. The MEMS mirror and the other optical component will be packaged into the MEMS-based probe; the probe will be attached with the existing OCT system, and then will be tested for lung imaging. The proposed MEMS-based OCT system has the potential to be a low-cost tool for rapid diagnosis or screening of lung cancer at the point of care. It is also expected that the technology could be used for other OCT systems for internal organ imaging. If successful the proposed MEMS design and wire bonding-free (WBF) packaging technique can be applied virtually to all optical imaging systems including coherence, confocal, nonlinear and adaptive optical imaging. They can also be used in laser scanning displays and optical telecommunications. This effort may lead to the world's first MEMS-based OCT applicable to rapid diagnosis or screening of lung cancer at the point of care (e.g., bedside or office). Due to its low-cost and disposable nature, it is particularly suitable for field use without the need of sterilization equipments. Although the focus of this proposal is on a MEMS based endoscopic OCT system for bronchoscopy, the key technology developed can be adapted for other compact OCT systems for internal organ imaging. The MEMS-based endoscopic OCT probe is applicable to diagnosis and image-guided surgery of various internal cancers such as prostate, colon, rectal, and gastro-intestinal cancers. Wioptix is a company that received a SBIR Phase I grant for a project entitled: Development of Miniature Endoscopic Imaging Probes for In Vivo Noninvasive Optical Imaging for Early Diagnosis of Lung Cancer. Their Phase I project an Optical coherence tomography (OCT) imaging MEMS-based probe of 2.8 mm diameter will be designed and manufactured. The plan is to apply MEMS design and wire bonding free packaging techniques for miniaturization of the probe. In this MEMS design the mirror will have high fill factor and bonding pads on the opposite chip side of the reflective mirror surface. The MEMS mirror and the other optical component will be packaged into the MEMS-based probe; the probe will be attached with the existing OCT system, and then will be tested for lung imaging. The proposed MEMS-based OCT system has the potential to be a low-cost tool for rapid diagnosis or screening of lung cancer at the point of care. It is also expected that the technology could be used for other OCT systems for internal organ imaging. If successful the proposed MEMS design and wire bonding-free (WBF) packaging technique can be applied virtually to all optical imaging systems including coherence, confocal, nonlinear and adaptive optical imaging. They can also be used in laser scanning displays and optical telecommunications. This effort may lead to the world's first MEMS-based OCT applicable to rapid diagnosis or screening of lung cancer at the point of care (e.g., bedside or office). Due to its low-cost and disposable nature, it is particularly suitable for field use without the need of sterilization equipments. Although the focus of this proposal is on a MEMS based endoscopic OCT system for bronchoscopy, the key technology developed can be adapted for other compact OCT systems for internal organ imaging. The MEMS-based endoscopic OCT probe is applicable to diagnosis and image-guided surgery of various internal cancers such as prostate, colon, rectal, and gastro-intestinal cancers. "This award is funded under the American Recovery and Reinvestment Act of 2009 (Public Law 111-5)."

B
Biospiral

BioSpiral's state-of-art system aims to provide prostate cancer treatment as a minimally invasive procedure, which uses cooling & heating technologies to destroy prostate cancer.nBioSpiral was established in Sep 2006 and is operating as part of NGT Incubator. nBioSpiral prostate thermodynamics therapy is an effective, minimally invasive treatment for prostate cancer that does not involve the difficulty and complications associated with surgery, nor the harmful properties of radiation or cryotherapy .The system revolutionizes prostate cancer treatment by introducing a "one shot" treatment method under local anesthesia at the physician's clinic. BioSpiral treatment is for patients with localized prostate cancer, who look for an effective minimal invasive therapy for prostate cancer. Additionally, this treatment can also be used by patients who have local recurrence after other treatments ("salvage" treatment). Key advantages:nCost effective: short treatment, no need for O.R or hospitalizationnHighly efficient: tissue ablationnPatients: high quality of life; minimal side effects, minimal invasive, short treatment & recovery.

m
m2m Imaging

Corp.m2m Imaging, with offices in USA and Australia produce's high-definition imaging and work flow solutions for life science applications in the MRI, PET, CT and SPECT analytical, preclinical and clinical research environments. m2m's MRI coil and accessory portfolio consists of products that have provided solutions to enable otherwise unobtainable results for research applications all over the world.

N
NeoGraft Technologies

NeoGraft Technologies is developing Angioshield, an intraperative system that creates a micro-fibrous, polymer sleeve intimately surrounding the outside surface of a harvested vein to mechanically reinforce and protect it from overdilation.

B
Brain Tunnelgenix Technologies

Brain Tunnelgenix Technologies develops medical devices and equipment. It provides non-invasive and continuous wearable technology that tracks human brain temperature through the brain's thermal tunnel. The company was founded in 2006 and is based in Aventura, Florida.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.